Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: terrapin who wrote (10597)	7/7/1998 8:39:00 AM
From: EyeDrMike	Read Replies (1) \| Respond to of 23519

Ahhhhhhhhhhh, i love the smell of burnt shorts early in the morning.

To: terrapin who wrote (10597)	7/7/1998 9:06:00 AM
From: Mkilloran	Read Replies (3) \| Respond to of 23519

.............8 1/4 so far in early trading.... I'am enjoying the 3rd qtr already....... To all the longs ...Have a good day

To: terrapin who wrote (10597)	9/2/1998 3:22:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

martin, Here is some very interesting factual information: Viagra script numbers for week ending 8/21 New 85,186 Refill 83,494 Total 168,680 This is the lowest new script count since Viagra's first full week of availability. It is also the lowest total since Viagra's second full week of availability. If you calculate a refill time lag of 6 weeks on the total refill numbers (calculate this by taking the total refill count as of 8/21 which is 1,104,387 and divide by the total new scripts going to 6 weeks before that which is 2,521,709 thru 7/10, you get 43.8%). In other words currently Viagra is showing only a 44% refill rate based on a 6 week refill time. If the placebo effect can be up to 30% then Viagra is only beating the placebo effect by 14%. I know that the placebo effect is probably not that high but even if it is only 20% that means that Viagra is only working on about 24% of the non psychogenic cases. This certainly is not even close to Pfizer's claims of 70 to 80% efficacy. With well over 1/2 of Viagra patients failing, I still see a huge potential for muse. The product has a good niche but can not fill it unless a domestic partner can get to most of the PCPs.